Evommune’s $12.38 share price sits below net cash, but the remaining EVO756 and EVO301 pipeline creates a high-risk binary catalyst trade.
Overview
Evommune, Inc. (EVMN) is a pre-revenue clinical-stage biotechnology company developing therapies for chronic inflammatory diseases, primarily atopic dermatitis, migraine prophylaxis, and previously chronic spontaneous urticaria. Its clinical-translation model in-licenses mid-stage assets and seeks value creation through clinical milestones, regional licensing, upfront payments, and royalties rather than commercial product sales. **The investment is a highly speculative, binary pipeline opportunity:** EVO756 failed its 160-patient Phase 2b CSU trial in June 2026, but remains in AD and migraine, while EVO301 produced positive Phase 2a AD proof-of-concept results in February 2026. The company ended Q1 2026 with $307.0 million of cash and investments, only $17.9 million of liabilities, and management expects funding through 2028. At approximately $12.38 after the CSU selloff, enterprise value was about $264.45 million versus approximately $289.1 million of net cash, implying the remaining pipeline is valued below zero. Near-term catalysts are EVO756’s Q3 2026 AD readout, continued migraine development, and EVO301’s planned mid-2027 Phase 2b. Analyst opinion is divided, with Morgan Stanley and Clear Street retaining Buy/Overweight views and $26.00 and $28.00 targets, while William Blair and H.C. Wainwright downgraded to Market Perform and Neutral/Hold.